AstraZeneca (AZN) RNS Announcements

Add to Alert list
Date Time Source Announcement
26 Jan 2018 07:00 AM
RNS
AZ Reports Phase III Results for PT010 in COPD
19 Jan 2018 07:00 AM
RNS
LYNPARZA APPROVED IN JAPAN FOR OVARIAN CANCER
19 Jan 2018 07:00 AM
RNS
ASTRAZENECA'S FASENRA RECEIVES APPROVAL IN JAPAN
12 Jan 2018 04:10 PM
RNS
FDA approves Lynparza for metastatic breast cancer
10 Jan 2018 03:10 PM
RNS
AstraZeneca's Fasenra approved in the EU
02 Jan 2018 03:00 PM
RNS
Total Voting Rights
28 Dec 2017 02:00 PM
RNS
Director/PDMR Shareholding
18 Dec 2017 07:00 AM
RNS
FDA accepts Tagrisso submission for 1st-line nsclc
15 Dec 2017 12:00 PM
RNS
Director/PDMR Shareholding
01 Dec 2017 03:00 PM
RNS
Block listing Interim Review
01 Dec 2017 03:00 PM
RNS
Total Voting Rights
28 Nov 2017 07:00 AM
RNS
EMA accepts Tagrisso submission for 1st-line nsclc
27 Nov 2017 07:00 AM
RNS
AZ submits Tagrisso in Japan for 1st-line nsclc
15 Nov 2017 07:00 AM
RNS
AZ Fasenra receives FDA approval for severe asthma
10 Nov 2017 11:35 AM
RNS
BENRALIZUMAB POSITIVE CHMP IN EOSINOPHILIC ASTHMA
09 Nov 2017 07:00 AM
RNS
AZN: Year-To-Date and Q3 2017 Results Announcement
01 Nov 2017 03:00 PM
RNS
Total Voting Rights
01 Nov 2017 07:03 AM
RNS
ASTRAZENECA AND ASPEN COMPLETE ANAESTHETICS DEAL
01 Nov 2017 07:00 AM
RNS
AstraZeneca tralokinumab update in severe asthma
31 Oct 2017 05:05 PM
RNS
US FDA approves AstraZeneca's Calquence for MCL
23 Oct 2017 07:05 AM
RNS
AZ and MSD rapidly advance Lynparza in Japan
23 Oct 2017 07:00 AM
RNS
US FDA approves Bydureon BCise for type-2 diabetes
18 Oct 2017 07:00 AM
RNS
FDA Priority Review for Lynparza in breast cancer
17 Oct 2017 07:00 AM
RNS
FDA accepts sBLA file for Imfinzi; priority review
09 Oct 2017 07:00 AM
RNS
FDA grants Tagrisso BTD for 1st-line EGFR nsclc
02 Oct 2017 03:00 PM
RNS
Total Voting Rights
26 Sep 2017 12:00 PM
RNS
Director/PDMR Shareholding
14 Sep 2017 07:00 AM
RNS
Aspen acquires remaining rights to AZ anaesthetics
11 Sep 2017 07:00 AM
RNS
IMFINZI superior PFS in Stage III lung cancer
11 Sep 2017 07:00 AM
RNS
Tagrisso potential standard of care in lung cancer
07 Sep 2017 12:39 PM
RNS
Celgene and AZ update on Fusion trial programme
07 Sep 2017 07:00 AM
RNS
AZ tezepelumab cuts exacerbations in severe asthma
07 Sep 2017 07:00 AM
RNS
AZ Duaklir improves lung function in COPD patients
05 Sep 2017 07:00 AM
RNS
Directorate Change
01 Sep 2017 03:00 PM
RNS
Total Voting Rights
29 Aug 2017 07:00 AM
RNS
Faslodex gets US FDA OK for expanded use in breast
18 Aug 2017 07:00 AM
RNS
Lynparza gets broad FDA approval in ovarian cancer
16 Aug 2017 07:00 AM
RNS
Directorate Change
14 Aug 2017 04:30 PM
RNS
Holding(s) in Company
10 Aug 2017 01:30 PM
RNS
Publication of a Prospectus
02 Aug 2017 07:00 AM
RNS
AZ acalabrutinib submission accepted by US FDA
01 Aug 2017 03:00 PM
RNS
Total Voting Rights
01 Aug 2017 07:00 AM
RNS
BTD for AZ's acalabrutinib in mantle cell lymphoma
31 Jul 2017 07:00 AM
RNS
Imfinzi granted BTD by US FDA for Stage III nsclc
28 Jul 2017 11:00 AM
RNS
Director/PDMR Shareholding
27 Jul 2017 07:15 AM
RNS
Tagrisso significantly improves FLAURA
27 Jul 2017 07:11 AM
RNS
AZ reports initial results from MYSTIC lung trial
27 Jul 2017 07:06 AM
RNS
AZ & MERCK ESTABLISH STRATEGIC ONCOLOGY DEAL
27 Jul 2017 07:00 AM
RNS
AstraZeneca PLC - H1 2017 Results
26 Jul 2017 04:46 PM
RNS
Faslodex receives EU approval for 1L breast cancer

AstraZeneca plc is a British-Swedish multinational pharmaceutical and biotechnology company with its headquarters at the Cambridge Biomedical Campus in Cambridge, England.

It has a portfolio of products for major diseases in areas including oncology, cardiovascular, gastrointestinal, infection, neuroscience, respiratory, and inflammation. It was involved in developing the Oxford–AstraZeneca COVID-19 vaccine.

Astra Zeneca share price launched at 605p in 1993.

UK 100